liver disease
FDA knocks back Mallinckrodt’s kidney drug terlipressin
Phil Taylor
kidney disease, liver disease, Mallinckrodt, regulatory, terlipressin
0 Comment
Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panel
Phil Taylor
fda, kidney disease, liver disease, Mallinckrodt, rare disease, terlipressin
0 Comment
Patients/ Views & Analysis/ Views and analysis
COVID-19 and vulnerable children: Urging caution while enjoying childhood
Amanda Barrell
coronavirus, COVID-19, liver disease, primary sclerosing cholangitis, ulcerative colitis
0 Comment
R&D/ Views & Analysis/ Views and analysis
Q&A: Novartis’ Eric Hughes on transplantation
George Underwood
kidney disease, liver disease, Novartis, transplantation
0 Comment
Conatus axes staff after latest failure of Novartis-partnered NASH drug
Phil Taylor
Conatus, liver disease, NASH, Novartis
0 Comment
Promethera looks to Asia with €10m investment
George Underwood
asia, Japan, liver disease, Promethera
0 Comment
Articles/ Novartis/ R&D/ Views and analysis
Novartis muscles into NASH fatty liver disease
Andrew McConaghie
hepatitis C, liver disease, NASH
0 Comment
Company’s Eric Hughes on what it takes to be leader in NASH – and what can be learnt from hepatitis C.